3D-printed silicone heart beats like the real thing

LinkedIn

Advanced 3D printing and manufacturing techniques that can produce soft machines could save a lot of lives in the future. They could be used to make not just soft robots for search and rescue, but also temporary organs for people on the transplant waiting list, like the artificial heart created and tested by a team of researchers from ETH Zurich. The researchers have developed a silicone heart that beats like the real organ does using a 3D-printing, lost-wax casting technique.

In the future, it could be used as an temporary heart instead of the blood pumps hospitals use today for patients waiting for a heart transplant. Since it’s a single solid silicone structure, it doesn’t have the usual disadvantages associated with typical pumps’ metallic and plastic mechanisms, which are susceptible to complications. That’s why when the team set out to create an artificial heart, they made it their goal to develop one that “is roughly the same size as the patient’s own one and which imitates the human heart as closely as possible in form and function.”

Continue onto Engadget to read the complete article.

 

The First Pharmacy to Add Drones for Delivery

LinkedIn
A drone holding a small UPS package flies in front of a CVS Pharmacy

CVS, in an effort to ensure proper medication is easily available to those who need it the most, has been utilizing in-store pickup, drive through services, and free delivery to distribute their prescriptions. But for the first time in history, in partnership with UPS, one CVS pharmacy will start delivering medication in a new way—by drone.

The Villages, the largest retirement facility in the United States, located in central Florida, will begin receiving their prescription medications from CVS via drone delivery starting in early May and is expected to continue until the COVID-19 pandemic ends. Drone delivery will enable more social distancing of especially susceptible members of the community and decrease the chances of infection on both sides. The drones will only be flying a half-mile distance to a separate location and transported by truck from there.

Though this technology is rarely used presently, this isn’t the first time that drone delivery has been tested. In fact, drone delivery was first utilized by UPS to make deliveries to WakeMed’s flagship campus in Raleigh, North Carolina, and at UC San Diego in California. These deliveries, as well as the ones that will be made in Florida, adhere to the Federal Aviation Administration’s Part 107 rules and have permission to be utilized during the pandemic.

Deployment of delivery drones during the pandemic could potentially open up to possibilities of drone delivery in the future and among other CVS pharmacies.

To read the full press release, click here

This New COVID-19 Test is Bringing Us Closer to the Cure

LinkedIn
African-american scientist or graduate student in lab coat and protective wear works in modern laboratory

The University of Washington’s Virology Lab has been working tirelessly since the COVID-19 pandemic began. It was one of the first labs to formulate a test for the presence of the virus and has processed thousands of these tests at its facilities. In fact, the university’s virology lab is currently processing its newest success in partnership with Abbott Labs’ antibody test for COVID-19.

The University has been running trials of Abbott Labs’ antibody blood tests, designed to find out who has natural or built-up immunity to COVID-19. The trials have proved to be incredibly successful.

Though showing immunity isn’t a cure, it is a major step to getting to that point. Knowing who is immune and who has had the virus before helps track the origins of the disease, knowing the components that can be used in a vaccine, and helps ensure the safety of bringing people back into the workforce. It is unclear how the antibodies of the novel coronavirus work or if you could get infected with the virus a second time, but Keith Jerome, the leader of the University of Washington’s virology program, assured that people with the antibodies will have more protection than those who do not. Receiving the virus a second time could result in more cold-like symptoms and not require the extreme hospitalization methods in place now.

The work being done in the study of antibodies through the University of Washington would not be possible without Abbott’s partnership. The antibody test produced by Abbott is not the first of its kind to be produced, but it is said to be the most reliable and the most sensitive in analyzation. In fact, Abbott’s test has correctly identified COVID-19 99.6% of the time against other viruses and has a 100% sensitivity to the coronavirus antibodies. Best of all, the test only takes about ten to fifteen minutes to retrieve the results.

“This starts to get us to the point that we can make a difference for the population of our area, get people back to work and give them back the lives that they were hoping for,” Jerome said.

NASA engineers in Pasadena area develop ventilator tailored to needs of COVID-19 patients

LinkedIn
NASA Engineers pictured at laboratory

The engineers at NASA have developed a high-pressure ventilator prototype specifically tailored to help coronavirus patients, according to the agency.

It’s called VITAL, or Ventilator Intervention Technology Accessible Locally.

And after passing a critical test at the Icahn School of Medicine at Mount Sinai in New York earlier this week, NASA is hoping for fast-track approval of the ventilator in the coming days so it can be used to help coronavirus patients.

Engineers at NASA’s Jet Propulsion Laboratory in the Pasadena area developed the ventilator, which can be built quickly using fewer parts, most of which are available in current supply chains, the agency said. But it won’t compete with the existing supply chain for ventilators.

“We were very pleased with the results of the testing we performed in our high-fidelity human simulation lab,” said Dr. Matthew Levin, director of innovation for the Human Simulation Lab and associate professor of anesthesiology, perioperative and pain medicine, and genetics and genomics sciences at the Icahn School of Medicine, in a statement.

“The NASA prototype performed as expected under a wide variety of simulated patient conditions. The team feels confident that the VITAL ventilator will be able to safely ventilate patients suffering from Covid-19 both here in the United States and throughout the world.”

The prototype works like traditional ventilators, where sedated patients rely on an oxygen tube to help them breathe. But it’s built to last three or four months unlike ventilators in hospitals that were designed to last for years and help patients with other medical issues. The engineers hope that more traditional ventilators can be freed up for patients with the most severe cases of coronavirus if VITAL is put into place.

The innovative ventilator was also designed to offer more oyxgen at higher pressures than typical models because Dr. Levin said some of the patients he’s treating needed that capability.

“Intensive care units are seeing Covid-19 patients who require highly dynamic ventilators,” said Dr. J.D. Polk, NASA’s chief health and medical officer, in a statement. “The intention with VITAL is to decrease the likelihood patients will get to that advanced stage of the disease and require more advanced ventilator assistance.”

It was also designed to be flexible with easy maintenance, meaning it can be used in the diverse settings hosting field hospitals, including hotels and convention centers.

“We specialize in spacecraft, not medical-device manufacturing,” Michael Watkins, JPL director, said in a statement. “But excellent engineering, rigorous testing and rapid prototyping are some of our specialties. When people at JPL realized they might have what it takes to support the medical community and the broader community, they felt it was their duty to share their ingenuity, expertise and drive.”

Rising to the challenge

Engineers like Stacey Boland stepped up, driven to do anything they could to help. The last 40 days have taken everything they had to make VITAL. The team worked long hours each day, which bled over into nonexistent weekends.

Boland is a project system engineer developing the MAIA instrument, the Multi-Angle Imager for Aerosols that will characterize particulate matter in air pollution. The instrument could provide the data that helps medical professionals determine what types of pollution correlate with negative health outcomes.

On MAIA, Boland has worked with epidemiologists to determine the data they would need from the mission.

On VITAL, Boland acted as the operations lead to create a communication pathway between engineers, designers and visualization specialists with doctors, nurses, respiratory therapists and intensivists (board-certified physicians providing special care for critically ill patients). Translating between the different professions to put everyone on the same page was a challenge, but one she enjoyed.

Operating during a pandemic meant that they were relying on calls, sending images and video conferencing to make a product in real time. Medical professionals called in on their lunch breaks, still in scrubs, describing what they were seeing in patients and what they would need VITAL to do.

A limited staff worked in person on the hardware, while the rest of the team video conferenced in. Boland was literally writing the instruction manual for how to operate VITAL as it was being built.

For Boland, it’s personal. Her sister is a hospitalist nurse practitioner at Memorial Hospital at Gulfport in Mississippi. She would call her sister, send her pictures and ask questions as they worked on the device, and her sister would send feedback in real time.

Boland calls it the experience of a lifetime, working on a team that was able to find camaraderie through their singular desire to create something helpful during such a challenging time.

When they encountered obstacles while working on VITAL, there was no sleeping on decisions that needed to be made, Boland said. Normal coping mechanisms were tossed out the window, and they worked through issues in real time to overcome the next challenge.

It’s been an adrenaline rush, working on a ventilator in such a short time, and the team wished it were under better circumstances. But the VITAL team was driven to help.

“I am not a medical device engineer, but when I hear someone on the front line needs something, I want them to have it,” Boland said. “We want to be there for them. It’s been a blessing and a privilege to have something so challenging and yet so relevant to be working on.”

Leon Alkalai, a technical fellow at JPL, manages the office of strategic partnerships. In recent years, he’s been leading a small effort to build relationships with the medical engineering community. He joined the VITAL team in a leadership role and helped establish communication between JPL and Mount Sinai, the FDA and the US Department of Homeland Security.

Alkalai said the FDA has been extremely supportive. And the doctors at Mount Sinai were interested in partnering together on VITAL after he reached out and shared the idea.

The collaboration between NASA and the FDA and medical professionals is an example of how institutions with different areas of expertise are coming together to create solutions for the pandemic.

“We’re rocket scientists and engineers, we know how to land on the moon and Mars,” Alkalai said. “But building a medical device is new. We were humbled by that challenge to do something we’ve never done before for a good cause. It goes against our culture to do something quickly in a domain where we’re not experts. But it fits with the JPL mantra: ‘Dare Mighty Things.’”

Currently, the California Institute of Technology, which manages JPL, is conducting outreach to find manufacturers for VITAL.

A helping hand

Additionally, NASA is trying to help fill the gaps due to shortages of other medical equipment in local communities, like Antelope Valley, California. One new device is the Aerospace Valley Positive Pressure Helmet, which can be used to help treat coronavirus patients with minor symptoms so they don’t have to use a ventilator. It functions more like a continuous positive airway pressure, or CPAP, machine, commonly used to treat sleep apnea, the agency said.

It has already been successfully tested and submitted to the FDA for emergency-use authorization. Meanwhile, 500 are currently in production.

The device is the result of a collaboration between NASA’s Armstrong Flight Research Center in California partnered with Antelope Valley Hospital, the City of Lancaster, Virgin Galactic and The Spaceship Company, Antelope Valley College and members of the Antelope Valley Task Force.

Continue on to KTLA News to read the complete article.

Jim Ryan and the Wheelie 7: A Game Changer for Mobility

LinkedIn
Jim Ryan, male, sitting in his HOOBOX Robotics' Wheelie 7 wheelchair in his living room, smiling for the camera

By Jaeson “Doc” Parsons

The date of March 30th, 2016, will be forever etched into the mind of Jim Ryan. That day, while vacationing in Maui with his wife, Isabelle, a wave struck him in waist deep water, driving him into the sea floor. He surfaced, unconscious and unresponsive. In that split second, Ryan was paralyzed, becoming a quadriplegic from his C4 vertebrae down. In that moment, his life was changed forever.

Ryan is not alone. According to the National Spinal Cord Injury Statistical Center, nearly 288,000 people in the United States are living with spinal cord injuries, and there about 17,700 new cases each year.

For those with movement-limiting conditions like Ryan, getting around can exact a terrible toll on quality of life and autonomy. A 2018 study found that physical mobility has the largest impact on quality of life for people with spinal cord injuries. Mobility is often enabled through caregivers or through a motorized wheelchair with complex sensors placed on the body that require special education to operate.

With this in mind, technology company Intel partnered with robotics company Hoobox to create the first-ever artificial intelligence-powered wheelchair that translates facial expressions into freedom of movement.

Using a combination of Intel hardware and software, Hoobox developed ‘The Wheelie’—a wheelchair kit that utilizes facial recognition technology to capture, process, and translate facial expressions into real-time wheelchair commands, finally providing individuals such as Ryan with autonomy, regardless of the physical limitations they’re facing. This system is a kit which can be installed on any motorized wheelchair system and, at under 7 minutes for installation, is relatively easy to implement.

Like many individuals suffering from spinal cord injuries, Ryan was using a conventional motorized system, one that uses a head array to translate gestures into movement.

“Before the Wheelie I drove my wheelchair with the head array. It is like a horseshoe around my head with five buttons that I used to turn left, right, forward, back, and change modes,” Ryan said. “Because of the head array, I am unable to look left and right. Nor can I wear hats of virtually any type. The hats get in the way of my buttons.”

Hoobox saw this limitation and found a way through it. By incorporating AI and a camera, the Wheelie 7 operates without invasive body sensors, providing users with independence and control over their location. It translates 11 different facial expressions into wheelchair commands in real time with 99.9% accuracy. And its performance improves over time as the algorithm learns to recognize the user’s expressions, allowing for increased freedom of movement.

“The Wheelie allows me to turn my head left and right and wear any hat I want,” said Ryan, who was introduced to Hoobox’s Wheelie through a group in Vancouver. He is one of more than 60 individuals who are testing the new technology to help Hoobox developers understand their needs and requirements.

Since being introduced to the Wheelie 7, Ryan has improved not just his mobility, but his lifestyle as well.

“I now can look left and right, up and down. I can wear a sun hat or baseball hat in the summer and nice winter hat or hoodie in the winter,” he said.

As technology continues its march forward with advances in AI systems, the limitations on mobility for those suffering from debilitating injuries like Ryan are beginning to see a transformation.

Wheelie 7 is a game changer in improving access to mobility solutions for those with conditions resulting from nearly 500,000 spinal cord injuries per year. But through continued research and development by companies such as Intel and Hoobox, and with the help of individuals such as Ryan, mobility is becoming a reality.

“For a person like me it gives a tremendous amount of freedom,” he said. “By using facial expressions instead of head movements, the Wheelie allows me more freedom and comfort in my wheelchair. And for anyone else with limited movement like me, it can be at true asset.”

General Atomics and Its Affiliates Unite in Fight Against COVID-19

LinkedIn
face shields in boxes

As the U.S. and the world take on the challenge of combating the novel coronavirus, General Atomics (GA) and its affiliates are leveraging their expertise in manufacturing and innovation to meet the urgent needs of our communities.

At GA facilities in San Diego and across the country, test kit development, 3D printing of Personal Protective Equipment (PPE) and ventilator component manufacturing are underway to assist in the fight against COVID-19 at a local, state and national level.

 

  • GA, Diazyme is offering a COVID-19 Antibody test from blood draws (serum or plasma). Under the FDA’s policy for Public Health Emergency for COVID-19, Diazyme utilized the notification process as outlined in Section IVD of the policy and is now listed on the FDA’s FAQ site dedicated to serological (Antibody) testing. The Diazyme’s sensitive test is run on a fully-automated Diazyme DZ-Lite 3000 chemiluminescence analyzer. Diazyme is already working with multiple clinical laboratories around the country, including the UCSD Medical Center to perform these serological tests. Serological tests are not for sole diagnosis of the COVID-19 disease but are valuable in understanding community spread of the disease.
  • Diazyme has also notified the FDA of a rapid COVID-19 Antibody test. This point-of-care test requires only a single drop of blood and provides results within 10-15 minutes. Rapid tests tend to be less sensitive than the lab run tests but are easy to use and can be performed at the point-of-care (doctor’s office, community clinics) and is useful in identifying people who may have been exposed to COVID-19, as well as those who have already recovered, but were unaware that they had been infected.
  • More information about Diazyme’s tests including regulatory statutory statements can be found at http://www.diazyme.com/dz-lite-sars-cov-2
  • GA, Electromagnetic Systems (GA-EMS) group is pursuing component manufacturing and integration services to help scale up production of ventilators. With extensive manufacturing facilities located across the U.S., GA-EMS provides a convenient, US-sourced option to help companies rapidly increase their production capacity to meet the high demand for critical medical equipment. GA-EMS has also tested their first generation mechanized bag valve mask. The system would fit into a backpack and could replace human interaction with the bag enabling more controlled and repeatable tides for infants, children and adults.
  • GA-EMS, GA-Energy group, and GA-ASI adapted their prototyping and production capacities to produce 3D-printed face shields to meet local demand for PPE. Since late March, the joint team has manufactured and shipped over 5,000 face shields in the greater San Diego area and across the nation.
  • GA-EMS is accelerating the development schedule of its MATCHBOX™ Point-of-Care molecular diagnostic platform responding to the growing need for COVID-19 testing. MATCHBOX is expected to have the capability to test and diagnose for a wide range of known respiratory infections, including COVID-19, within 30-60 minutes using a single patient sample using a portable point-of-care instrument.

“The health, safety and well-being of our employees and our communities at large is a top priority for GA,” said Neal Blue, GA Chairman and CEO. “GA has been delivering solutions in support of public health for decades, and with so many in need during this unprecedented time, we have concentrated our collective efforts to address the current pandemic. I salute colleagues as they continue to innovate and look for creative solutions to the current crisis.”

About General Atomics Electromagnetic Systems

General Atomics pioneers in the development of transformational technologies. Since the dawn of the atomic age, GA’s innovations have advanced the state of the art across the full spectrum of science and technology – from nuclear energy and defense to medicine and high-performance computing. Behind a talented global team of scientists, engineers, and professionals, GA delivers safe, sustainable, and economical solutions to meet growing global demands. www.ga.com.

This Town Is Already Getting Deliveries By Drones

LinkedIn
Drone carrying first aid package

In Christiansburg, Virginia, deliveries by drones are not only being studied but also implemented for the town’s citizens amid social distancing due to COVID-19.

The deliveries technically began in October, when a drone nicknamed “Wing” carried a fleece vest for the last two miles of the item’s delivery route. This marked “Wing” as the first drone to ever carry out this kind of delivery in the United States. Ever since this incident, the drone has continued to deliver packages over short distances, especially during this time of social distancing.

Besides Christiansburg, drone deliveries have only been officially tested in areas of Finland and Australia, as researchers are still looking into the mechanics of using drones for everyday deliveries. All of the towns conducting tests, including Christiansburg, have a flat topography and relatively small populations, making them ideal spots to test drone delivery without geographic or social interruption from largely populated cities. Virginia Tech, the home to an unnamed drone research department, also resides in close proximity to Christiansburg, as to closely study the effects of drone delivery.

While drone delivery has so far proved successful, it does have its controversies. For one, the delivery drones would not be able to deliver any item, having a weight limit of about three pounds. Drones must also pass the test of public perception as tests try to seek the normalization of drone delivery by everyone. Regardless, “Wing” and its correspondents have already partnered with  major companies, such as Walgreens and FedEx, to deliver essential items, and the search has already begun for more testing sites across the United States.

Natalie Rodgers
Diversity in STEAM Magazine contributing writer

From A Simple Swab To A Simple Sniff—How dogs are being trained to detect COVID-19

LinkedIn
dogs face close up

Especially for the elderly and to those with compromised immune systems, coronavirus testing kits are critical to treating the virus at an early stage. The current test is excellent at its job but is limited to and inaccessible to many people around the world—not to mention it’s uncomfortable. But what if there were an easier way?

Many scientific journals have proposed each disease has its own distinct scent. Many dogs have been used in the past to detect different types of cancer, Parkinson’s disease, and bacterial ailments. That is why the organization Medical Detection Dogs, located in the United Kingdom, have begun trials with medical professionals to see if dogs can sniff out the coronavirus’ scent.

The hope is that dogs will pick up on COVID-19’s scent among large crowds and detect those carrying the virus. This procedure would not only be more comfortable than current testing but could also cover more ground and be less invasive.

Should these dogs be successful, Professor Steve Lindsay of Durham University believes that, “…we could use COVID-19 detection dogs at airports at the end of the epidemic to rapidly identify people carrying the virus. This would help prevent the re-emergence of the disease after we have brought the present epidemic under control.”

Natalie Rodgers
Diversity in STEAM Magazine contributing writer

Breweries and distilleries around the world are producing free sanitizing products to fight the coronavirus

LinkedIn
anheuser-busch diageo sanitizer bottles

The world’s largest beer and spirits companies have both announced they’ll be pivoting some of their production and logistics to produce millions of bottles of hand sanitizer around the world. The moves come as many brands look at ways to mobilize their extensive resources to help battle the global spread of the coronavirus that causes COVID-19.

Diageo, parent company of spirits brands ranging from Johnnie Walker to Smirnoff, today announced it will provide 2 million liters (about half a million gallons) of 96% alcoholic grain-neutral spirit to sanitizer manufacturers at no cost. That amount is enough to produce 8 million bottles of sanitizer at 250 milliliters each.

Anheuser-Busch—creator of Budweiser, Bud Light, Michelob Ultra and many other beer brands—is retooling its global manufacturing and distribution networks to create more than 1 million bottles of hand sanitizer that will be donated. Although the company doesn’t create distilled spirits, the sanitizer production was accomplished by shifting what it described as “existing technology for our non-alcohol brewing process.”

Both corporations said the sanitizer they’re producing at no charge will go to hospitals and frontline medical personnel, who have struggled worldwide to maintain adequate supplies of protective equipment as consumers stocked up on sanitizer, masks and other products.

“Healthcare workers are at the forefront of fighting this pandemic, and we are determined to do what we can to help protect them,” said Ivan Menezes, CEO of Diageo. “This is the quickest and most effective way for us to meet the surging demand for hand sanitizer around the world.”

Diageo and Anheuser-Busch aren’t the first alcohol companies to begin producing free sanitizer amid the COVID-19 outbreak, but they’re certainly the largest.

Delaware craft brewer Dogfish Head and many local breweries or distillers have been working to produce sanitizer for their communities and medical facilities. Tito’s Vodka says it’s currently testing a production change that will allow it to produce an initial run of 24 tons (about 6,500 gallons) of sanitizer in small bottles.

Here’s a breakdown of how the two massive global companies will be structuring their sanitizer production efforts:
Diageo

• U.K. and Ireland: Providing 500,000 liters of grain-neutral spirits for national healthcare systems and workers.
• Italy: Supplying 100,000 liters of grain-neutral spirits to support the healthcare system and other national needs.
• U.S.: Providing 500,000 liters for local community needs.
• Brazil: Diageo’s Ypioca plant will produce 50,000 liters of grain-neutral spirit for the local healthcare system, in conjunction with the Ceara state government.
• Kenya: Diageo’s East Africa Breweries will enable production of 135,000 liters of sanitizer, prioritizing vulnerable and at-risk groups.
• India: Providing 500,000 liters of alcohol to supply to the sanitizer industry across 25 states, for use in national healthcare systems and for consumers.
• Australia: Diageo’s Bundaberg Distilling will produce 100,000 liters of ethanol for the Queensland government, to be directed to hand sanitizer manufacturers.
• Africa: Producing disinfectant alcohol, then using extensive fleet and route network of breweries to deliver the finished product to the most remote parts of the continent.
• Europe: Producing 50,000 liters of disinfectant alcohol as well as 26,000 bottles of hand sanitizer for donation to pharmacies and frontline workers across the region.
• Central America: Producing more than 400,000 bottles of hand sanitizer gel for donation to hospitals and local governments.
• North America: Producing and distributing bottles of hand sanitizer to accommodate growing needs across the United States and Canada.
• South America: Produced 500,000 bottles of hand sanitizer for hospitals in the most impacted areas, including Sao Paulo, Rio de Janeiro and Brasilia in Brazil.

Continue on to ADWEEK to read the complete article.

Cisco commits $225 million to battle coronavirus, leading tech’s fight against the pandemic

LinkedIn
Cisco representative seated announcing pandemic support

Cisco plans to dedicate $225 million in cash and services to support various causes dedicated to combating the spread of the coronavirus and helping those affected.

“Cisco must, and will, do even more to help others respond to this global pandemic,” said Cisco CEO Chuck Robbins, pictured, in a blog post published Sunday evening.

The investment, which includes $8 million in cash and $210 million in products, will be dispersed to a variety of groups including the United Nations Foundation’s COVID-19 Solidarity Response Fund and the World Health Organization’s various coronavirus efforts.

“People who were already vulnerable are facing even more risks to their health, stability, housing, and well-being,” Robbins wrote. “Nonprofits are struggling to serve their populations as the number of volunteers declines due to social distancing practices and donations are at-risk due to financial concerns.”

The networking giant will also provide funding for unspecified “heads of state, government agencies, and businesses to rapidly deploy COVID-19-related technology solutions,” Robbins wrote.

According to Robbins, Cisco is helping to secure over 2.2 million people online to date, and Webex, the company’s video conference and online collaboration tool, has facilitated the virtual response meetings for the French, Canadian, German, Colombian, and other governments around the world.

Cisco, along with other unnamed companies, will also announce on Monday a multi-million-dollar financial assistance program for at-risk people, Robbins said.

“With support from Santa Clara County Supervisor Cindy Chavez, San Jose Mayor Sam Liccardo, and Destination: Home’s CEO Jen Loving, we will be able to rapidly support low-income individuals during this time,” he wrote.

Cisco’s announcement comes after various tech companies and figures have announced their efforts to combat the spread of the virus and support overwhelmed medical professionals worldwide.

Amazon was among the earliest to respond, announcing on March 10 that it would create a $5 million grant to help small businesses in the Seattle area that were affected by the coronavirus.

A week later, Jack Ma, the CEO of Chinese e-commerce and cloud computing giant Alibaba, pledged to donate emergency supplies to various countries in Asia that have been severely impacted by the coronavirus.

Microsoft CEO Satya Nadella described in a LinkedIn post on Saturday several ways his company was helping others who are fighting the coronavirus. “In healthcare, our technology is being used for telemedicine, enabling user-intuitive solutions to share data and access critical information,” Nadella wrote. “St. Luke’s University Health Network in Pennsylvania is using Teams to video chat with patients most vulnerable to COVID-19.”

Apple CEO Tim Cook tweeted on Saturday that his company was “donating millions of masks for health professionals in the U.S. and Europe.”

On Sunday, Facebook CEO Mark Zuckerberg followed suit, saying his social media company has “donated our emergency reserve of 720,000 masks that we had bought in case the wildfires continued.”

The move by Cisco could be just the start of the company’s coronavirus pandemic response efforts, noted Robbins. “While our world will be different as we move into the future,” he wrote, “it is important that we stay focused on making a positive impact in every way possible.”

Continue on to Fortune for more Coronavirus coverage.

View Cisco’s Response to Committing $225 million to global COVID-19 On Their Executive Platform

 

Dr. Seema Yasmin Answers 50 of the Most Googled Coronavirus Questions

LinkedIn
Dr. Seema Yasmin answering questions about the COVID-19

Dr. Seema Yasmin, Professor of Medicine, Stanford University,  is back to help answer 50 of the most popular coronavirus questions being searched right now.

Over the next few weeks she will be responding directly to your questions as they are sent to her.

Today she goes over the first 50 questions of the ones that have been asked so far including;

Do coronavirus symptoms come and go?

Why is it called coronavirus?

Why do they call it “Novel”?

When was it first discovered?

Has this virus been around before?

Get the answers to these questions, and submit yours today.

WATCH THE VIDEO HERE!